Lysine-Proline-Valine — a tripeptide fragment of alpha-MSH studied for potent NF-kB-mediated anti-inflammatory activity, gut barrier protection, and systemic inflammation control.
What is KPV, and why has it become the distinguishing component of the KLOW Stack? KPV is a tripeptide — three amino acids: Lysine-Proline-Valine — derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied for its ability to inhibit NF-kB, the master regulator of inflammatory gene expression, at nanomolar concentrations. This potency, combined with unusual oral bioavailability for a peptide and specific gut anti-inflammatory activity, makes KPV the dedicated inflammation control component of the KLOW Stack and an increasingly recognised entity in longevity and anti-ageing research.
| TL;DRKPV (Lysine-Proline-Valine) is a synthetic tripeptide derived from the C-terminal sequence of alpha-MSH. Its primary mechanism is inhibition of NF-kB — the master transcription factor controlling hundreds of pro-inflammatory genes — at nanomolar concentrations. Research demonstrates anti-inflammatory activity in gut, skin, and systemic contexts. It is orally bioavailable — unusual for peptides — making it applicable to gut-targeted protocols. KPV is the defining fourth component of the KLOW Stack. |
| Parameter | Detail |
| Full name | Lysine-Proline-Valine |
| Abbreviation | KPV |
| Structure | Synthetic tripeptide — 3 amino acids: Lys-Pro-Val |
| Natural origin | C-terminal tripeptide sequence of alpha-melanocyte-stimulating hormone (alpha-MSH) |
| Primary mechanism | NF-kB inhibition — suppresses master inflammatory transcription factor |
| Active concentration | Nanomolar — biologically active at one-billionth of a gram per litre |
| Research status | Preclinical; early-stage human data for gut inflammation applications |
| Oral bioavailability | Demonstrated — unusual among research peptides |
| Purity standard | Greater than 98% for research grade; greater than 99% in standard KLOW pre-blend |
| Stack role | Defining fourth component of the KLOW Stack — inflammation control layer |
KPV is a synthetic tripeptide consisting of three amino acids: Lysine (K), Proline (P), and Valine (V). Its sequence corresponds to the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH) — a naturally occurring peptide hormone produced in the pituitary gland and skin that plays a role in pigmentation, inflammation regulation, and immune modulation.
While alpha-MSH has a complex range of biological activities, research has identified its C-terminal KPV tripeptide as the primary sequence responsible for its anti-inflammatory properties. By isolating and synthesising this tripeptide, researchers can study its anti-inflammatory activity in concentrated, controlled form without the broader hormonal effects of the full alpha-MSH sequence.
Alpha-MSH (alpha-melanocyte-stimulating hormone) is a naturally occurring 13-amino acid peptide derived from pro-opiomelanocortin (POMC). It is produced in the pituitary gland, skin keratinocytes, and other tissues. Its roles include regulation of skin pigmentation, appetite modulation, and — importantly — anti-inflammatory signalling through the melanocortin receptor system.
The discovery that the C-terminal tripeptide KPV retains the anti-inflammatory potency of the full alpha-MSH molecule — while lacking the melanogenic and other hormonal activities — made it an attractive candidate for targeted anti-inflammatory research. KPV can be produced synthetically with high purity and studied in isolation from the complex activity profile of the parent hormone.
KPV’s primary and best-characterised mechanism is direct inhibition of NF-kB (Nuclear Factor kappa B) — the master transcription factor that controls the expression of hundreds of pro-inflammatory genes.
| What NF-kB Does and Why Inhibiting It MattersNF-kB is activated by a wide range of inflammatory stimuli — infection, injury, oxidative stress, and chronic metabolic dysfunction. When activated, it drives the production of IL-6, TNF-alpha, IL-1beta, and other pro-inflammatory cytokines. Chronic low-grade NF-kB activation — inflammaging — is implicated in age-related tissue decline, impaired healing, metabolic dysfunction, and cardiovascular disease. KPV’s direct NF-kB inhibition addresses inflammation at its regulatory source, not just at the level of individual cytokines. |
KPV’s NF-kB inhibition mechanism involves translocation to the cell nucleus where it directly blocks NF-kB activity — inhibiting transcription of inflammatory genes before they are expressed. This upstream mechanism distinguishes it from anti-inflammatory compounds that target individual cytokines downstream.
| Research Area | Key Finding |
| Gut inflammation | Research published in the Journal of Clinical Investigation demonstrated significant reduction in intestinal inflammation in murine colitis models treated with KPV, with effects through NF-kB pathway inhibition. |
| Skin inflammation | KPV has demonstrated anti-inflammatory activity in skin tissue models, reducing inflammatory markers in keratinocytes and supporting wound healing through inflammation modulation. |
| Safety profile | Animal studies have confirmed KPV is non-toxic and non-irritating even at concentrations significantly above typical research doses, supporting its favourable safety profile. |
| Nanomolar potency | Research has demonstrated KPV biological activity at nanomolar concentrations — approximately one-billionth of a gram per litre — indicating high potency relative to its molecular size. |
| Oral absorption | Studies have confirmed meaningful oral absorption of KPV, distinguishing it from most peptides which are degraded in the gastrointestinal tract before reaching systemic circulation. |
KPV’s gut-specific research is one of its most distinctive attributes. Unlike the other components of KLOW, which address gut health primarily through systemic repair pathways, KPV has been studied directly in gut inflammation models and demonstrates both oral bioavailability and specific anti-inflammatory activity in intestinal tissue.
Most peptides are rapidly degraded by proteolytic enzymes in the gastrointestinal tract before they can be absorbed into systemic circulation. This is why most research peptides require subcutaneous or intramuscular injection to achieve biological activity.
KPV is unusual in demonstrating meaningful oral bioavailability — it survives gastrointestinal transit to a sufficient degree to produce systemic effects after oral administration. This has two practical implications:
Within the KLOW Stack, KPV occupies the fourth and most recently added layer — the inflammation controller. Its role is to create the optimal inflammatory environment for the three repair-focused components to work effectively.
| Without KPV (GLOW) | With KPV (KLOW) |
| Repair signals present but potentially operating in a high-inflammation environment | NF-kB inhibition reduces the inflammatory brake on repair mechanisms |
| No dedicated NF-kB pathway inhibition | Direct upstream suppression of hundreds of pro-inflammatory genes |
| Appropriate where inflammation is moderate | Preferred where chronic inflammation is limiting repair response |
| Three mechanisms: angiogenesis, mobilisation, collagen | Four mechanisms: adds inflammation control at the gene expression level |
KPV is increasingly referenced in longevity protocols targeting inflammaging — the chronic low-grade NF-kB-driven inflammation that characterises biological ageing. Its applications beyond the KLOW Stack context include:
| Quality Parameter | Specification |
| Minimum purity | Greater than 98% by reversed-phase HPLC for standalone research use |
| Purity in KLOW pre-blend | Greater than 99% per component in standard commercial 80mg blend |
| Molecular weight | 357.44 Da |
| Amino acid sequence | Lys-Pro-Val (tripeptide) |
| Verification method | Reversed-phase HPLC (C18 column, 214nm); confirmed by mass spectrometry |
| CoA requirement | HPLC chromatogram, MS data, batch-specific quantity verification |
| Standalone Factual Statements |
KPV is a tripeptide — Lysine-Proline-Valine — derived from the C-terminal sequence of alpha-MSH. Its primary action is inhibition of NF-kB, the master regulator of inflammatory gene expression, at nanomolar concentrations. This produces suppression of IL-6, TNF-alpha, and other pro-inflammatory mediators at the gene expression level, making it one of the most targeted anti-inflammatory peptides in research use.
KPV is added to the GLOW Stack to create KLOW specifically to address the fourth primary barrier to tissue repair: chronic inflammation. The three components of GLOW address blood supply, cell mobilisation, and collagen synthesis — but they do not directly inhibit the NF-kB inflammatory pathway that can suppress all three of those repair mechanisms. KPV fills this gap, allowing the repair-focused components to operate in a lower-inflammation environment.
Yes. KPV demonstrates meaningful oral bioavailability — it survives gastrointestinal transit to produce biological activity after oral administration. This is unusual among research peptides, most of which require injection. Oral KPV is particularly relevant for gut-targeted protocols, where it can act directly on intestinal epithelial tissue before entering systemic circulation.
KPV is the C-terminal tripeptide sequence of alpha-MSH — a naturally occurring 13-amino acid hormone. Research identified this three-amino acid C-terminal sequence as the primary carrier of alpha-MSH’s anti-inflammatory properties. By isolating and synthesising KPV, researchers can study its NF-kB inhibitory activity without the broader hormonal effects of the full alpha-MSH molecule.
| Term | Definition |
| KPV | Lysine-Proline-Valine. A synthetic tripeptide derived from alpha-MSH that inhibits NF-kB at nanomolar concentrations. The defining anti-inflammatory component of the KLOW Stack. |
| NF-kB | Nuclear Factor kappa B. The master transcription factor controlling hundreds of pro-inflammatory genes. KPV’s direct inhibition of NF-kB is its primary mechanism of action. |
| alpha-MSH | Alpha-melanocyte-stimulating hormone. A naturally occurring 13-amino acid pituitary peptide with roles in pigmentation, appetite, and inflammation. KPV is derived from its C-terminal tripeptide sequence. |
| Tripeptide | A peptide consisting of three amino acids. KPV is a tripeptide: Lysine-Proline-Valine. |
| Inflammaging | The chronic low-grade NF-kB-driven inflammation associated with biological ageing. A primary target of KPV in longevity protocols. |
| IL-6 | Interleukin-6. A pro-inflammatory cytokine suppressed by KPV through NF-kB inhibition. Chronically elevated IL-6 is associated with age-related tissue degeneration. |
| Oral bioavailability | The proportion of an orally administered compound that reaches systemic circulation. KPV demonstrates meaningful oral bioavailability — unusual for research peptides. |
| POMC | Pro-opiomelanocortin. The precursor protein from which alpha-MSH is cleaved. The broader peptide family from which KPV is ultimately derived. |
| Related Entity Pages-> KLOW Stack — BPC-157, TB-500, GHK-Cu, KPV hplcpeptides.com/wiki/klow-stack-> GLOW Stack — BPC-157, TB-500, GHK-Cu hplcpeptides.com/wiki/glow-stack
-> Wolverine Stack — BPC-157 + TB-500 hplcpeptides.com/wiki/wolverine-stack -> BPC-157 — Tissue Repair and Gut Health hplcpeptides.com/wiki/bpc-157 -> GHK-Cu — Collagen Synthesis and Regeneration hplcpeptides.com/wiki/ghk-cu -> Peptide Testing — Purity, Quantity and Integrity hplcpeptides.com/wiki/peptide-testing -> Peptides — The Master Reference Guide hplcpeptides.com/wiki/peptides |
| About This PageThis entity page is maintained by the HPLC Peptides editorial team. All research references are preclinical or early-stage. This page does not constitute medical advice. |
hplcpeptides.com/wiki/kpv | Entity Page v1.0 | April 2026
